Scailyte CHU Rennes announce Covid-19 partnership. Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 3.1 million in a pre-Series A round led by Swisscom Ventures.
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is
supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning
several national and international start-up competitions, and is the beneficiary of significant research
grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial
Intelligence, Software development, Finance, Marketing and Sales.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised
pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and
have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
True precision medicine through single-cell science - Nature
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m
Recent News
Scailyte AG Announces a partnership with Sirona DX
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single
Recent News
WEBINAR: Supervised learning of disease-associated cell states and dynamics
Watch Scailyte's webinar on "Supervised learning of disease-associated cell states and dynamics" wit
Recent News
PODCAST: Discovering diseases with artificial intelligence
PODCAST: Discovering diseases with artificial intelligence. Listen to this episode of Binary Dreams
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
True precision medicine through single-cell science - Nature
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m
Scailyte AG Announces a partnership with Sirona DX
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single
Recent News
WEBINAR: Supervised learning of disease-associated cell states and dynamics
Watch Scailyte's webinar on "Supervised learning of disease-associated cell states and dynamics" wit
PODCAST: Discovering diseases with artificial intelligence
PODCAST: Discovering diseases with artificial intelligence. Listen to this episode of Binary Dreams